Association between COVID-19 and the incidence of type 1 diabetes in Portugal – a registry study

Morten Bjerregaard-Andersen*, Jessica Da Silva, Rui Diogo, Ana Raquel Claro, Inês Ferro, Andreia Romana, Patrícia Rocha, Beatriz Sá, Goreti Lobarinhas, Sara Rolim, Claus Bogh Juhl, Kurt Højlund, Isabel Fernandes, Sónia Antunes, Maria Manuela Félix Calha, Guida Gama, Sofia Amálio, Mariana Figueiras, Teresa Silva, Margarida RosadoEstela Ferrão, Luísa Arez, Ana Baptista, Adriana Martins Ferreira, Diana Alba, Carlos Godinho, Ana Luísa Leite, Maria de Lurdes Afonso Lopes, Maria Lurdes Sampaio, Joana Serra-Caetano, Eugenia Carvalho

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

6 Downloads (Pure)

Abstract

Background: Viral respiratory infections may precipitate type 1 diabetes (T1D). A possible association between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, and the incidence of T1D is being determined. This study was carried out using Portuguese registries, aiming at examining temporal trends between COVID-19 and T1D. Methods: Hospital data, comparing the incidence before and during the COVID-19 pandemic, from children and young adults diagnosed with new-onset T1D, was acquired beginning in 2017 and until the end of 2022. Data was obtained from nine different Portuguese hospital units. The impact of the COVID-19 pandemic, beginning in March 2020, was assessed comparing the annual numbers of new-onset T1D cases. The annual median levels of glucose, glycated hemoglobin (HbA1c) and fasting C-peptide at T1D diagnosis were compared. The annual number of diabetic ketoacidosis (DKA) episodes among new T1D cases was also assessed at two centers. Results: In total, data from 574 newly diagnosed T1D patients was analyzed, including 530 (92.3%) children. The mean ages for child and adult patients were 9.1 (SD 4.4) and 32.8 (SD 13.6) years, respectively. 57.8% (331/573) were male, one patient had unknown sex. The overall median (25–75 percentiles) levels of glucose, HbA1c and fasting C-peptide at diagnosis were 454 mg/dL (356–568), 11.8% (10.1–13.4) and 0.50 µg/L (0.30–0.79), respectively. DKA at T1D diagnosis was present in 48.4% (76/157). For eight centers with complete 2018 to 2021 data (all calendar months), no overall significant increase in T1D cases was observed during the COVID-19 pandemic, i.e. 90 cases in 2018, 90 cases in 2019, 112 in 2020 and 100 in 2021 (P for trend = 0.36). Two of the centers, Faro (CHUA) and Dona Estefânia (CHULC) hospitals, did however see an increase in T1D from 2019 to 2020. No significant changes in glucose (P = 0.32), HbA1c (P = 0.68), fasting C-peptide (P = 0.20) or DKA frequency (P = 0.68) at the time of T1D diagnosis were observed over the entire study period. Conclusion: The T1D incidence did not increase significantly, when comparing the years before and during the COVID-19 pandemic, nor did key metabolic parameters or number of DKA episodes change.

OriginalsprogEngelsk
Artikelnummer145
TidsskriftBMC Endocrine Disorders
Vol/bind24
ISSN1472-6823
DOI
StatusUdgivet - dec. 2024

Fingeraftryk

Dyk ned i forskningsemnerne om 'Association between COVID-19 and the incidence of type 1 diabetes in Portugal – a registry study'. Sammen danner de et unikt fingeraftryk.

Citationsformater